Media and Press
Somnera’s new system “is a game changer” with the 22 million people dealing with sleep apnea, Cox says. “Sleep apnea is one of the most important healthcare markets, and patients with sleep apnea are more than tired: sleep apnea makes a host of other conditions, ranging from diabetes to dementia, worse. The problem is that most patients don’t want or can’t tolerate existing treatments.
Somnera’s recent clinical study demonstrated effectiveness in treating obstructive sleep apnea. “This is the second randomized trial that demonstrates the safety and efficacy of Somnera in treating sleep apnea. Sleep apnea is often tough to treat because some patients cannot tolerate CPAP and many abandon treatment.
“As the number of sleep apnea diagnoses grows and reliance on CPAP continues to increase, the number of people who struggle with long-term adherence to CPAP therapy also increases. We are proud to work with Somnera on the launch of this disruptive, low-flow technology that can potentially benefit thousands of CPAP patients who are unsatisfied with traditional CPAP therapy,” said Anthony Zadnik, CEO of Agile Medical. “Somnera will be available for purchase and supported exclusively at The CPAP Shop.”
Press Kits and Press Releases
Electronic Press Kit
Team photos and bios
Press Release – 9.29.20
Somnera Announces US Launch of New Treatment Technology for Sleep Apnea